DOI: https://doi.org/10.22141/2224-1485.3-4.64-65.2019.177847

Dynamics of left ventricular remodeling in patients with arterial hypertension associated with type 2 diabetes and obesity under the influence of one-year combined therapy

S.M. Koval, T.G. Starchenko, K.O. Yushko, O.V. Mysnychenko, M.Yu. Penkova, V.Yu. Galchinska, I.A. Korneichuk, O.M. Shenyavska, O.M. Lytvynova

Abstract


Background. Pathological left ventricular remodeling in patients with arterial hypertension combined with type 2 diabetes and obesity is associated with a significant increase in cardiovascular risk and requires early and adequate drug correction. Materials and methods. The study included 38 patients with stage 2 hypertension associated with type 2 diabetes and abdominal obesity. The examination was carried out before and after one-year therapy with angiotensin II receptor blocker olmesartan and calcium antagonist lercanidipine in combination with atorvastatin and metformin. Results. Patients showed a high frequency of pathological types of left ventricular remodeling (concentric and eccentric left ventricular hypertrophy — 50 and 37 %, respectively) with the development of left ventricular diastolic dysfunction in 89 % of cases. Combined therapy contributed to a significant decrease in the severity of left ventricular hypertrophy and the frequency of diastolic dysfunction. Conclusions. Long-term use of olmesartan and lercanidipine in combination with atorvastatin and metformin in patients with arterial hypertension associated with type 2 diabetes and abdominal obesity is an effective method of inhibiting the progression of pathological left ventricular remodeling.


Keywords


arterial hypertension; type 2 diabetes mellitus; obesity; left ventricular remodeling; diastolic dysfunction; olmesartan; lercanidipine; atorvastatin; metformin

References


Cifkova R. Epidemiology of hypertension. Manual of hypertension of the European Society of Hypertension. 2014. P. 1-13.

Сіренко Ю.М. Артеріальні гіпертензії при ендокринних захворюваннях. К.: Четверта хвиля, 2004. 165 с.

Williams B., Mancia G., Spiering W., Agabiti Rosei E. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 2018. Vol. 39. P. 3021-3104.

Серцево-судинні захворювання. Класифікація, стандарти діагностики та лікування. 3-тє вид., переробл. і доповн. К.: Моріон, 2018. 224 с.

Маньковский Б.Н. Артериальная гипертензия у больных сахарным диабетом 2 типа — особенности течения и терапии. ДОМС. 2013. № 4(ІІ). С. 10-13.

Koval S., Iushko K., StarchenkoT. Relations of apelin with cardiac remodeling in patients with hypertension and type 2 diabetes. Folia Medica. 2018. Vol. 60(1). P. 117-123.

Vуsotska O.V., Koval S.M., Bespalov Yu.G., Pecherska A.I., Lytvynova O.M., Dyvak A.M. Mathematical simulation of the structure of pulsed arterial pressure relations with vascular damage factors in patients with arterial hypertension. In book: Information Technology in Medical Diagnostics II. Wójcik, Pavlov& Kalimoldayev (Eds), 2019 Taylor & Francis Group, London, ISBN 978-0-367-17769-0: pp. 47-52. doi: 10.1201/9780429057618-32.

Koval S.M., Snihurska I.O., Vysotska O., Strashnenko H.M., Wójcik W., Dassibekov K. Prognosis of essential hypertension progression in patients with abdominal obesity. In book: Information Technology in Medical Diagnostics II, Wójcik, Pavlov& Kalimoldayev (Eds), 2019 Taylor & Francis Group, London, ISBN 978-0-367-17769-0: pp. 275-288. doi: 10.1201/9780429057618-32.

Koval S., Snihurska I., Yushko K., Lytvynova O., Bere­zin A. Plasma microRNA-133а level in patients with essential arterial hypertension. Georgian medical news. 2019. Vol. 5 (290). P. 52-59.

American Diabetes Association. Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan. Vol. 41 (Suppl. 1). P. S1-S159.

Victor R.G. Systemic hypertension: Mechanisms and diagnosis. In: Braunwald's heart disease: a textbook of cardiovascular medicine. 2015. P. 934-952.

Коваленко В.Н. Сердечно-сосудистые заболевания и ренин-ангиотезиновая система. К.: Морион, 2013. 232 с.

de la Sierra A., Barrios V. Blood pressure control with angiotensin receptor blocker-based three-drug combinations: key trials. Adv. Ther. 2012. Vol. 29(5). P. 401-415. doi: 10.1007/s12325-012-0019-7.

Smith R.D., Yokoyama H., Averill D.B., Cooke L., Brosnihan K.B., Schiffrin E.L., Ferrario C.M. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics. Am. J. Cardiovasc. Drugs. 2006. Vol. 6(5). P. 335-42.

Radchenko G.D., Mushtenko L.O., Sirenko Yu.M. Influence of fixed-dose combination perindopril/amlodipine on target organ damage in patients with arterial hypertension with and without ischemic heart disease (results of EPHES trial). Vascular Health and Risk Management. 2018. Vol. 14. P. 265-278.

Ettehad D., Emdin C.A., Kiran A., Anderson S.G., Callender T., Emberson J., Chalmers J., Rodgers A., Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016. Vol. 387. P. 957-967.

Bangalore S., Fakheri R., Toklu B., Messerli F.H. Diabetes mellitusas a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of rando-mized trials. BMJ. 2016. Vol. 352. i1525.

Коваль С.М., Снігурська І.О., Пенькова М.Ю., Літвінова О.М., Божко В.В., Юшко К.О. Артеріальна гіпертензія та цукровий діабет: питання оптимізації контролю артеріального тиску. Артериальная гипертензия. 2018. 2(58). 9-18.

Ruilope L. Fixed-Combination Olmesartan/Amlodipine Was Superior to Perindopril + Amlodipine in Reducing Central Systolic Blood Pressure in Hypertensive Patients With Diabetes. J. Clin. Hypertens. (Greenwich). 2015. P. 1-8.

Saseen J.J. Review of Olmesartan Medoxomil in Achieving Guideline Recommended Target BP Goals and Implications for Managed Care Current. Hypertension Reviews. 2012. Vol. 8. P. 190-195.

Raff U., Walker S., Ott C., Schneider M.P., Schmieder R.E. Olmesartan improves pulse wave velocity and lowers central systolic blood pressure and ambulatory blood pressure in patients with metabolic syndrome. J. Clin. Hypertens (Greenwich). 2015. Vol. 17(2). P. 98-104. doi: 10.1111/jch.12458.

Сіренко Ю.М. Про нові європейські рекомендації з артеріальної гіипертензії після їх першої презентації (коментар). Артериальная гипертензия. 2018. 3(59). 19-22.

Peng M.I., Jiang X.J., Dong H. et al. Lercanidipine improve renal function in patients with atherosclerotic renal artery stenosis undergoing renal artery intervention. Curr. Med. Res. Opin. 2015. Vol. 31(1). P. 177-82.

Драпкина О.М. Статины и риск развития сахарного диабета. Рациональная фармакотерапия в кардиологии. 2013. 4 (9). 444-447.

Worsley R., Jane F., Robinson P.J., Bell R.J., Davis S.R. Metformin for overweight women at midlife: a double-blind, randomized, controlled trial. Climacteric. 2015 Apr. Vol. 18(2). P. 270-7. doi: 10.3109/13697137.2014.954997.

Júnior V.C., Fuchs F.D., Schaan B.D., Moreira L.B., Fuchs S.C., Gus M. Effect of metformin on blood pressure in patients with hypertension: a randomized clinical trial. Endocrine. 2019. Vol. 63(2). P. 252-258.

Sakata Y., Shiba N., Takahashi J. et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Eur. Heart J. 2015. Vol. 36. P. 915-923.




Copyright (c) 2019 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2020

 

   Seo анализ сайта